Barclays Capital Reaffirms Equalweight Rating on AstraZeneca (AZN)
Several other analysts have also recently commented on the stock. Analysts at Exane BNP Paribas reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday, January 22nd. They now have a $50.66 price target on the stock. Separately, analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca in a research note to investors on Monday, January 21st. They now have a $42.39 price target on the stock. Finally, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Wednesday, January 9th. They now have a $45.91 price target on the stock.
AstraZeneca opened at 3143.50 on Tuesday. AstraZeneca has a 1-year low of GBX 2578.50 and a 1-year high of GBX 3156.50. The stock’s 50-day moving average is currently GBX 0.. The company’s market cap is £39.137 billion.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.